Novavax Inc

XNASHealth care

Last traded price · USD

$11.14

+4.60%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 18:34 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $10.65
Volume: 66,656
Day's high: —
Day's low: —

In brief

Novavax Inc is a health care company listed on Nasdaq, valued at about $1.84B.
Its shares closed at $10.65 on 4 Nov 2026, up 41.8% over the past year.
From India you can buy NVAX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Novavax Inc (NVAX) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole NVAX share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade NVAX options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −5.9% (SPY −1.6%, XLV +13.5%). 3 months: +38.3% (SPY −0.4%, XLV +15.5%). 1 year: +41.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: NVAX, SPY and XLV · as of 4 Nov 2026
Short interest at 28.7% of shares outstanding
47.3M shares were sold short at the 15 Oct 2026 settlement, 28.7% of the 164.9M shares outstanding; covering them would take 4.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $10.65 was 1.3% above its 50-day average ($10.51) and 14.2% above its 200-day average ($9.32). It has closed above the 200-day for 53 sessions, since 21 Aug 2026. The 50-day average crossed above the 200-day on 24 Sep 2026, 29 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
62% of the way up its 52-week range
Closed at $10.65 on 4 Nov 2026: 20.4% below the 52-week high of $13.39 (5 Oct 2026) and 71.8% above the low of $6.20 (20 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−5.9%

6 months+13.8%

1 year+41.8%

5 years−94.1%

Newswire

About

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Website

Notable moves

May 13, 2024
+47.64%
May 10, 2024
+98.66%
December 15, 2022
−34.30%

Newswire

About

Website

Notable moves

May 13, 2024
+47.64%
May 10, 2024
+98.66%
December 15, 2022
−34.30%

Novavax Inc

XNASHealth care

Last traded price · USD

$11.14

+4.60%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 18:34 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $10.65
Volume: 66,656
Day's high: —
Day's low: —

In brief

Novavax Inc is a health care company listed on Nasdaq, valued at about $1.84B.
Its shares closed at $10.65 on 4 Nov 2026, up 41.8% over the past year.
From India you can buy NVAX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Novavax Inc (NVAX) shares from India?

Do I need the price of a whole NVAX share to invest?

How much can I invest in US stocks in a year?

Can I trade NVAX options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −5.9% (SPY −1.6%, XLV +13.5%). 3 months: +38.3% (SPY −0.4%, XLV +15.5%). 1 year: +41.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: NVAX, SPY and XLV · as of 4 Nov 2026
Short interest at 28.7% of shares outstanding
47.3M shares were sold short at the 15 Oct 2026 settlement, 28.7% of the 164.9M shares outstanding; covering them would take 4.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $10.65 was 1.3% above its 50-day average ($10.51) and 14.2% above its 200-day average ($9.32). It has closed above the 200-day for 53 sessions, since 21 Aug 2026. The 50-day average crossed above the 200-day on 24 Sep 2026, 29 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
62% of the way up its 52-week range
Closed at $10.65 on 4 Nov 2026: 20.4% below the 52-week high of $13.39 (5 Oct 2026) and 71.8% above the low of $6.20 (20 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−5.9%

6 months+13.8%

1 year+41.8%

5 years−94.1%

Newswire

About

Website

Notable moves

May 13, 2024
+47.64%
May 10, 2024
+98.66%
December 15, 2022
−34.30%

Newswire

About

Website

Notable moves

May 13, 2024
+47.64%
May 10, 2024
+98.66%
December 15, 2022
−34.30%

Novavax Inc

Novavax Inc in brief

Ahead of SPY and its sector fund XLV over 1 year

Short interest at 28.7% of shares outstanding

Above its 50- and 200-day averages

62% of the way up its 52-week range

Novavax Inc

Novavax Inc in brief

Ahead of SPY and its sector fund XLV over 1 year

Short interest at 28.7% of shares outstanding

Above its 50- and 200-day averages

62% of the way up its 52-week range